Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts.
about
High interstitial fluid pressure - an obstacle in cancer therapyPhase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma.TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects.Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives.Technology insight: Utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities.Changing the pathophysiology of solid tumours: the potential of TNF and other vasoactive agents.Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma.Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed.Laboratory models of regional chemotherapy.Manipulation of the tumour-associated vasculature to improve tumour therapy.Intratumoral drug delivery with nanoparticulate carriers.Solid tumor therapy: manipulation of the vasculature with TNF.Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy.Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor.Tumor necrosis factor-alpha in isolated perfusion systems in the treatment of cancer: the Rotterdam preclinical-clinical program.Combination of Gold Nanoparticle-Conjugated Tumor Necrosis Factor-α and Radiation Therapy Results in a Synergistic Antitumor Response in Murine Carcinoma Models.A simple method for measuring interstitial fluid pressure in cancer tissues.Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabineTumor vasculature-targeted recombinant mutated human TNF-α enhanced the antitumor activity of doxorubicin by increasing tumor vessel permeability in mouse xenograft models.Combretastatin-A4 phosphate improves the distribution and antitumor efficacy of albumin-bound paclitaxel in W256 breast carcinoma model.Peptide-mediated targeting of cytokines to tumor vasculature: the NGR-hTNF example.Synthesis and Evaluation of Paclitaxel-Loaded Gold Nanoparticles for Tumor-Targeted Drug Delivery.Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration.Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalpha.Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies.Adjuvant TNF-α therapy to electrochemotherapy with intravenous cisplatin in murine sarcoma exerts synergistic antitumor effectiveness.Paradoxical roles of tumour necrosis factor-alpha in prostate cancer biology.Exposing the tumor microenvironment: how gold nanoparticles enhance and refine drug delivery.Peritumoral TNFalpha administration influences tumour stroma structure and physiology independently of growth in DMBA-induced mammary tumours.Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas.Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery.High-dose, short-term, anti-inflammatory treatment with dexamethasone reduces growth and augments the effects of 5-fluorouracil on dimethyl-alpha-benzanthracene-induced mammary tumors in rats.Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan.
P2860
Q29619719-3210CE04-16F4-4CCD-845A-9CF98C9F21E9Q33147885-D6687B64-BF3F-4660-8AFB-0E6C040D1E5EQ33180038-E0429B41-C1BD-4491-AEDE-9926FE3AD94FQ33182076-9E2BE5A8-5217-4D89-A777-82B8201F198DQ33233270-41B6E04E-545B-4E0E-9724-99DFFE991FB6Q33245795-21228269-BB10-4B4E-A55B-6F130FE22A3DQ33309291-5B9AEBDF-B235-4476-B8A2-5899EFB6661DQ33325343-1A55E26E-961B-40BD-9723-6738F3D5AF07Q33327123-2AC954B7-E08B-4B82-91E6-75C85D87103DQ35072789-FC5A14EA-7FEF-4B10-BC57-41E4A5BAE0D8Q35091415-06E38E38-CEFA-4A4D-BEF1-C06130AE91E9Q35142322-F73CBA22-0463-48CC-A28F-F099BDE65E47Q35974293-58E82D4E-5FFC-412E-96B1-5A35684FD60AQ36043818-1BA76F33-AAEC-4835-BBE4-0CFA1A1408B9Q36896191-CDACE417-0F9F-4D7D-A998-6D0279262601Q37068894-76CBC84A-AFC7-49FD-AB44-1C713A812C9DQ37207583-664FD1E3-2438-442C-BBB7-A77F72BC3922Q37236248-47B25C85-F4CE-489E-81E1-BFBD9804804AQ37506109-87001ADC-7631-44C1-983F-8E22775AF5E5Q37628989-FD531B26-CE29-4CEC-A8AF-00D98CA4BB26Q38112578-7238295A-F5CB-40AB-8BBE-D51779636F3CQ38740409-0E8B0CFE-3814-420E-ADB9-536F4D961BBCQ39735956-CD7BF89C-08D1-4371-B399-AF51C3926C93Q39781613-BB3B2E0E-430B-4D1C-8A68-A28F2D9880B1Q40174625-F494B917-14AF-46E5-8CF7-116842B4CD01Q41903537-CA18CBE9-E9CD-4D9A-8838-CAE55C424571Q42713856-4684DFEC-A279-49A4-9853-8C1F1D67F5E4Q45059667-09640CCE-ED43-4C54-A285-4F7C101EF700Q46044956-26441B6F-A979-4315-AE57-77B8F9A9AB17Q46869122-338A373A-1D54-4629-9D4D-4F24E3C99376Q47325811-29968038-CD7C-4489-A922-7C3B5C944C75Q51784672-2CFB7197-DBD7-4906-9C2C-4BA59D446721Q51969642-5D655B7C-15E1-4CB5-9006-8E7DDF4F14AF
P2860
Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Reduction of interstitial flui ...... ree human melanoma xenografts.
@ast
Reduction of interstitial flui ...... ree human melanoma xenografts.
@en
type
label
Reduction of interstitial flui ...... ree human melanoma xenografts.
@ast
Reduction of interstitial flui ...... ree human melanoma xenografts.
@en
prefLabel
Reduction of interstitial flui ...... ree human melanoma xenografts.
@ast
Reduction of interstitial flui ...... ree human melanoma xenografts.
@en
P2093
P2860
P356
P1476
Reduction of interstitial flui ...... ree human melanoma xenografts.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.1996.397
P407
P577
1996-08-01T00:00:00Z